S$10 million Series C investment in Biobot Surgical co-led by ClavystBio
Allen & Gledhill, as transaction counsel, advised ClavystBio Investments Pte. Ltd. (“ClavystBio”), a life sciences investor and venture builder set up by Temasek, which co-led the S$10 million Series C fundraising in Biobot Surgical Pte. Ltd. (“Biobot”).
Biobot is a Singapore-based medical device company dedicated to transforming the field of robotic-assisted biopsy and treatment for prostate cancer.
Advising ClavystBio was Allen & Gledhill Partner Nicholas Soh.
